Treatment of leptomeningeal carcinomatosis with continuous intraventricular infusion of recombinant interleukin-2. 1991

J J Heimans, and J Wagstaff, and W O Schreuder, and J G Wolbers, and J W Baars, and C H Polman, and J G Scharenberg, and R J Scheper, and P A Palmer, and C R Franks
Department of Neurology, Free University Hospital, Amsterdam, The Netherlands.

A 42-year-old man developed leptomeningeal carcinomatosis 6 years after treatment of a malignant melanoma. He was treated with two courses of recombinant interleukin-2, administered as a continuous intraventricular infusion (6 X 10E5 U/24 h) during 5 days. During the first day of the first course he also received 5 X 10E9 lymphokine-activated killer cells intraventricularly. This gave rise to a severe elevation of intracranial pressure, with headaches and meningismus. During the second course no LAK cells were administered. This course was tolerated much better. The neurological status did not change during the treatment. Recombinant interleukin-2 levels were maintained at about 300 U/mL during both courses.

UI MeSH Term Description Entries
D007263 Infusions, Parenteral The administration of liquid medication, nutrient, or other fluid through some other route than the alimentary canal, usually over minutes or hours, either by gravity flow or often by infusion pumping. Intra-Abdominal Infusions,Intraperitoneal Infusions,Parenteral Infusions,Peritoneal Infusions,Infusion, Intra-Abdominal,Infusion, Intraperitoneal,Infusion, Parenteral,Infusion, Peritoneal,Infusions, Intra-Abdominal,Infusions, Intraperitoneal,Infusions, Peritoneal,Intra Abdominal Infusions,Intra-Abdominal Infusion,Intraperitoneal Infusion,Parenteral Infusion,Peritoneal Infusion
D007376 Interleukin-2 A soluble substance elaborated by antigen- or mitogen-stimulated T-LYMPHOCYTES which induces DNA synthesis in naive lymphocytes. IL-2,Lymphocyte Mitogenic Factor,T-Cell Growth Factor,TCGF,IL2,Interleukin II,Interleukine 2,RU 49637,RU-49637,Ro-23-6019,Ro-236019,T-Cell Stimulating Factor,Thymocyte Stimulating Factor,Interleukin 2,Mitogenic Factor, Lymphocyte,RU49637,Ro 23 6019,Ro 236019,Ro236019,T Cell Growth Factor,T Cell Stimulating Factor
D007427 Intracranial Pressure Pressure within the cranial cavity. It is influenced by brain mass, the circulatory system, CSF dynamics, and skull rigidity. Intracerebral Pressure,Subarachnoid Pressure,Intracerebral Pressures,Intracranial Pressures,Pressure, Intracerebral,Pressure, Intracranial,Pressure, Subarachnoid,Pressures, Intracerebral,Pressures, Intracranial,Pressures, Subarachnoid,Subarachnoid Pressures
D008297 Male Males
D008545 Melanoma A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445) Malignant Melanoma,Malignant Melanomas,Melanoma, Malignant,Melanomas,Melanomas, Malignant
D008577 Meningeal Neoplasms Benign and malignant neoplastic processes that arise from or secondarily involve the meningeal coverings of the brain and spinal cord. Intracranial Meningeal Neoplasms,Spinal Meningeal Neoplasms,Benign Meningeal Neoplasms,Leptomeningeal Neoplasms,Malignant Meningeal Neoplasms,Meningeal Cancer,Meningeal Neoplasms, Benign,Meningeal Neoplasms, Intracranial,Meningeal Neoplasms, Malignant,Meningeal Tumors,Neoplasms, Leptomeningeal,Neoplasms, Meningeal,Benign Meningeal Neoplasm,Cancer, Meningeal,Cancers, Meningeal,Intracranial Meningeal Neoplasm,Leptomeningeal Neoplasm,Malignant Meningeal Neoplasm,Meningeal Cancers,Meningeal Neoplasm,Meningeal Neoplasm, Benign,Meningeal Neoplasm, Intracranial,Meningeal Neoplasm, Malignant,Meningeal Neoplasm, Spinal,Meningeal Neoplasms, Spinal,Meningeal Tumor,Neoplasm, Benign Meningeal,Neoplasm, Intracranial Meningeal,Neoplasm, Leptomeningeal,Neoplasm, Malignant Meningeal,Neoplasm, Meningeal,Neoplasm, Spinal Meningeal,Neoplasms, Benign Meningeal,Neoplasms, Intracranial Meningeal,Neoplasms, Malignant Meningeal,Neoplasms, Spinal Meningeal,Spinal Meningeal Neoplasm,Tumor, Meningeal,Tumors, Meningeal
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D002552 Cerebral Ventricles Four CSF-filled (see CEREBROSPINAL FLUID) cavities within the cerebral hemispheres (LATERAL VENTRICLES), in the midline (THIRD VENTRICLE) and within the PONS and MEDULLA OBLONGATA (FOURTH VENTRICLE). Foramen of Monro,Cerebral Ventricular System,Cerebral Ventricle,Cerebral Ventricular Systems,Monro Foramen,System, Cerebral Ventricular,Systems, Cerebral Ventricular,Ventricle, Cerebral,Ventricles, Cerebral,Ventricular System, Cerebral,Ventricular Systems, Cerebral
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

J J Heimans, and J Wagstaff, and W O Schreuder, and J G Wolbers, and J W Baars, and C H Polman, and J G Scharenberg, and R J Scheper, and P A Palmer, and C R Franks
January 1989, European journal of cancer & clinical oncology,
J J Heimans, and J Wagstaff, and W O Schreuder, and J G Wolbers, and J W Baars, and C H Polman, and J G Scharenberg, and R J Scheper, and P A Palmer, and C R Franks
June 1988, The American journal of medicine,
J J Heimans, and J Wagstaff, and W O Schreuder, and J G Wolbers, and J W Baars, and C H Polman, and J G Scharenberg, and R J Scheper, and P A Palmer, and C R Franks
January 1993, Nephron,
J J Heimans, and J Wagstaff, and W O Schreuder, and J G Wolbers, and J W Baars, and C H Polman, and J G Scharenberg, and R J Scheper, and P A Palmer, and C R Franks
July 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
J J Heimans, and J Wagstaff, and W O Schreuder, and J G Wolbers, and J W Baars, and C H Polman, and J G Scharenberg, and R J Scheper, and P A Palmer, and C R Franks
January 1991, Pediatric nephrology (Berlin, Germany),
J J Heimans, and J Wagstaff, and W O Schreuder, and J G Wolbers, and J W Baars, and C H Polman, and J G Scharenberg, and R J Scheper, and P A Palmer, and C R Franks
January 1994, European journal of cancer (Oxford, England : 1990),
J J Heimans, and J Wagstaff, and W O Schreuder, and J G Wolbers, and J W Baars, and C H Polman, and J G Scharenberg, and R J Scheper, and P A Palmer, and C R Franks
May 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer,
J J Heimans, and J Wagstaff, and W O Schreuder, and J G Wolbers, and J W Baars, and C H Polman, and J G Scharenberg, and R J Scheper, and P A Palmer, and C R Franks
March 1992, Cancer research,
J J Heimans, and J Wagstaff, and W O Schreuder, and J G Wolbers, and J W Baars, and C H Polman, and J G Scharenberg, and R J Scheper, and P A Palmer, and C R Franks
January 2018, Frontiers in oncology,
J J Heimans, and J Wagstaff, and W O Schreuder, and J G Wolbers, and J W Baars, and C H Polman, and J G Scharenberg, and R J Scheper, and P A Palmer, and C R Franks
June 1994, Oncology nursing forum,
Copied contents to your clipboard!